Please assess the completion status of the following clinical trial:

Trial Title: Drug Interaction Study With BI 201335 and Methadone or Buprenorphine/Naloxone

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. stable dose of either methadone or buprenorphine/naloxone for 30 days for opioid maintenance therapy.~2. Male and female volunteers with a body mass index (BMI) = 18.5 and \< 32 with a minimum weight of 50kg.~Exclusion criteria:~1. any other significant medical illness of clinical significance.~2. history of rash or photosensitivity~3. chronic or acute infections including HIV, hepatitis B and hepatitis C.~4. history of allergy considered significant for this study~5. intake of any other medications except for methadone or buprenorphine/naloxone.~6. QTc on electrocardiogram (ECG) \> 470.~7. use of any other investigational drug within 30 days of the study.~8. drug or alcohol abuse (other than the defined opioid maintenance therapy with either methadone or buprenorphine/naloxone)~9. blood donation of more than 100mL within four weeks of the trial.~10. excessive physical activities one week prior to and during the trial.~11. any clinically relevant laboratory value.~12. concomitant use of any food product known to alter P450 or P-gp activity such as grapefruit juice, seville oranges and St. John's Wort.~13. inadequate venous access~    For women of childbearing potential:~14. pregnancy or planning to become pregnant within 3 months of the trial~15. positive pregnancy test at screening visit~16. no proof of sterilization or unwilling or unable to use a double barrier method of birth control during the study and up to 3 months after the study.~17. lactation with active breastfeeding from screening up to 30 days after last study visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Methadone group (Type: ACTIVE_COMPARATOR): patients on stable methadone therapy (at least 30 days) up to a maximum of 180mg per day
- Buprenorphine (Type: ACTIVE_COMPARATOR): patients on stable buprenorphine/naloxone therapy (at least 30 days) up to a maximum dose of 24mg/6mg per day.

Based on this trial design, predict the completion outcome and termination type (if applicable).